HLA class II transgenic mouse models for S. aureus infections and superantigens
HLA class II transgenic mouse models for S. aureus infections and superantigens
批准号:
8468981
负责人:
CHELLA S DAVID
金额:
$37.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2017-04-30
关键词:
AddressAllelesAnimal ModelAntibiotic ResistanceAntibodiesBacteriaBenignBindingBiochemicalBiologicalBone MarrowCellsChimera organismClinicalDiseaseDisease OutcomeEnterocytesExotoxinsExposure toFamilyFunctional disorderGenetic PolymorphismGoalsHLA-DQ AntigensHLA-DQ6HLA-DQ8 antigenHLA-DR AntigensHLA-DR2 AntigenHLA-DR3 AntigenHLA-DR4 AntigenHealthHumanImmune responseImmunityImmunologic MarkersIncidenceIndividualInfectionInfectious Skin DiseasesInflammationInstitutesInterferon Type IIInterferonsIntestinesInvestigationKidneyLifeLiverLungMHC Class II GenesMediatingMediator of activation proteinMindModelingMolecularMouse StrainsMusOrganOrganismOutcomePathogenesisPathogenicityPathologyPathway interactionsPatientsPlayPneumoniaPrevention strategyProductionResistanceRoleRouteSepsisSeriesStaphylococcal Enterotoxin BStaphylococcus aureusStreptococcus pyogenesSuperantigensSyndromeT-Cell ActivationT-LymphocyteTNFRSF10A geneTherapeuticTherapeutic UsesTimeToxic Shock SyndromeToxinTransgenic MiceVirulencechemokinecohortcytokineimmunopathologyin vivoinsightinterestmethicillin resistant Staphylococcus aureusmortalitymouse modelnovelreceptorresistant strainresponseweapons
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Staphylococcus aureus is a ubiquitous Gram-positive organism implicated in a spectrum of diseases; from benign, localized skin infections to life-threatening, systemic illnesses including pneumonia, sepsis and menstrual or non-menstrual toxic shock syndromes (TSS). The virulence and pathogenicity of S. aureus is attributed to its several exotoxins. The superantigen exotoxins (SAg) are important amongst them because SAg are the most potent activators of T lymphocytes known. Certain SAg could also be used as biological weapons. Thus, SAg are important from many perspectives. Nonetheless, the molecular pathways by which SAg participate in the disease pathogenesis have not been completely understood due to lack of good animal models. The conventional mouse strains are resistant to TSS due to poor binding of SAg to mouse MHC class II. However, SAg binds more efficiently to human MHC (called HLA) class I molecules. Therefore, mice transgenically expressing HLA class II molecules readily succumb to the pathogenic effects of SAg delivered through different routes and to S. aureus infection. As the disease caused by SAg in HLA class II (HLA-DR3) transgenic mice also closely mimics the syndrome in humans, they are ideal models. Using this mouse model we have demonstrated that interferon-gamma (IFN-?) dependent small intestinal pathology plays a critical role in lethality associated with TSS. However, the molecular pathways by which INF-¿ contributes to lethality in TSS, either directly or indirectly through other mediators, are not clear. Therefore, it is proposed to (1) Delineate th mechanisms by which IFN-¿ plays a lethal role in staphylococcal SAg-induced TSS. This will be achieved by generating bone marrow chimeras between HLA-DR3.IFN-?R+/+ and HLA-DR3.IFN-?R-/- mice. Bone marrow chimeras will be challenged with SEB and several molecular pathways will be compared. However, IFN-? is also important for immunity S. aureus infections. Therefore, it is proposed to (2) Determine the role of IFN-? in the pathogenesis and immunity to MRSA-induced pneumonia and sepsis. This wil be accomplished by inducing pneumonia and sepsis in HLA-DR3.IFN-?+/+ and HLA-DR3.IFN-?R-/- mice with the MRSA isolate, USA300. Several bacteriological, immunological, biochemical and pathological parameters including mortality will be compared between these two lines of mice. It is known that HLA class II polymorphisms could strongly influence the magnitude of T cell activation and IFN-? production in response to streptococcal SAg. However, the impact of HLA-DR and HLA-DQ polymorphisms on staphylococcal SAg-driven immuneresponses has not been investigated. Therefore, it is proposed to (3) Determine the extent to which staphylococcal superantigen-induced IFN-? production is modulated by HLA class II polymorphisms thereby influencing the outcome of MRSA-induced pneumonia and sepsis. This will be investigated by a series of in vivo studies using transgenic mice expressing HLA-DR2, HLA-DR3, HLA-DR4, HLA-DQ2, HLA-DQ6 or HLA-DQ8 molecules.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A humanized transgenic mouse model for studying staphylococcal enterotoxin B
-
批准号:7497343
-
项目类别:
-
资助金额:$22.67万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mouse models for S. aureus infections and superantigens
-
批准号:8646845
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mice as models for bacterial superantigen induced disease
-
批准号:7382578
-
项目类别:
-
资助金额:$21.78万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mice as models for bacterial superantigen induced disease
-
批准号:7596265
-
项目类别:
-
资助金额:$21.78万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mice as models for bacterial superantigen induced disease
-
批准号:8033187
-
项目类别:
-
资助金额:$21.34万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mice as models for bacterial superantigen induced disease
-
批准号:7792489
-
项目类别:
-
资助金额:$21.56万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mice as models for bacterial superantigen induced disease
-
批准号:7212656
-
项目类别:
-
资助金额:$22.2万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mouse models for S. aureus infections and superantigens
-
批准号:8366719
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2007
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA class II genes in demyelination
-
批准号:7099930
-
项目类别:
-
资助金额:$19.98万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA Class II Genes in Demyelination
-
批准号:8036554
-
项目类别:
-
资助金额:$34.5万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA class II genes in demyelination
-
批准号:7193400
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA class II genes in demyelination
-
批准号:7432539
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA class II genes in demyelination
-
批准号:7587522
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA Class II Genes in Demyelination
-
批准号:8715867
-
项目类别:
-
资助金额:$33.47万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA Class II Genes in Demyelination
-
批准号:8145634
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA Class II Genes in Demyelination
-
批准号:8544508
-
项目类别:
-
资助金额:$32.62万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
Role of HLA Class II Genes in Demyelination
-
批准号:8306283
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2006
-
负责人:CHELLA S DAVID
-
依托单位:
HLA class II transgenic mice as experimental model of MS
-
批准号:6652311
-
项目类别:
-
资助金额:$19.52万
-
财政年份:2002
-
负责人:CHELLA S DAVID
-
依托单位:
Core--Transgenic animal model
-
批准号:6652313
-
项目类别:
-
资助金额:$19.52万
-
财政年份:2002
-
负责人:CHELLA S DAVID
-
依托单位:
Core--Transgenic animal model
-
批准号:6481263
-
项目类别:
-
资助金额:$19.52万
-
财政年份:2001
-
负责人:CHELLA S DAVID
-
依托单位:
海外基金